US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
US7214686B2
(en)
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
US6632823B1
(en)
*
|
1997-12-22 |
2003-10-14 |
Merck & Co., Inc. |
Substituted pyridine compounds useful as modulators of acetylcholine receptors
|
US6277870B1
(en)
*
|
1998-05-04 |
2001-08-21 |
Astra Ab |
Use
|
FR2804430B1
(fr)
*
|
2000-01-28 |
2002-03-22 |
Sanofi Synthelabo |
Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
|
GB0010955D0
(en)
|
2000-05-05 |
2000-06-28 |
Novartis Ag |
Organic compounds
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
WO2002016357A2
(en)
*
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
WO2002016358A2
(en)
*
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
WO2002016356A2
(en)
*
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
US6599916B2
(en)
|
2000-08-21 |
2003-07-29 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
WO2002016355A2
(en)
*
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
|
WO2002017358A2
(en)
*
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
BR0212101A
(pt)
|
2001-08-24 |
2004-08-24 |
Pharmacia & Up John Company |
7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
|
JP2005504059A
(ja)
*
|
2001-08-24 |
2005-02-10 |
ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー |
疾患を処置するための置換アリール7−アザ[2.2.1]ビシクロヘプタン
|
CA2460075A1
(en)
*
|
2001-09-12 |
2003-03-20 |
Donn Gregory Wishka |
Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
|
DK1432707T3
(da)
*
|
2001-10-02 |
2012-06-11 |
Pharmacia & Upjohn Co Llc |
Azabicyklisk-substituerede kondenserede heteroarylforbindelser til behandling af sygdomme
|
US6849620B2
(en)
|
2001-10-26 |
2005-02-01 |
Pfizer Inc |
N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
|
MXPA04004464A
(es)
|
2001-11-08 |
2004-08-11 |
Upjohn Co |
Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
|
US6951868B2
(en)
|
2001-11-09 |
2005-10-04 |
Pfizer Inc. |
Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
|
NZ554913A
(en)
|
2001-12-14 |
2009-01-31 |
Targacept Inc |
Methods and compositions for the treatment of central nervous system disorders
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
BR0307714A
(pt)
|
2002-02-15 |
2005-02-09 |
Upjohn Co |
Benzoilamidas substituìdas com azabiciclo e tioamidas para tratamento de distúrbios relacionados ao cns
|
CA2476681A1
(en)
*
|
2002-02-19 |
2003-08-28 |
Bruce N. Rogers |
Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
|
WO2003070731A2
(en)
*
|
2002-02-19 |
2003-08-28 |
Pharmacia & Upjohn Company |
Azabicyclic compounds for the treatment of disease
|
JP2005525357A
(ja)
*
|
2002-02-20 |
2005-08-25 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
α7ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物
|
DE10211416A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Essig- und Propionsäureamide
|
DE10211415A1
(de)
*
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Bicyclische N-Biarylamide
|
AU2003253686A1
(en)
|
2002-08-01 |
2004-02-23 |
Pharmacia & Upjohn Company Llc |
1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
|
EP2298759A1
(en)
|
2002-08-30 |
2011-03-23 |
Memory Pharmaceuticals Corporation |
Anabaseine derivatives useful in the treatment of neurodegenerative diseases
|
GB0220581D0
(en)
|
2002-09-04 |
2002-10-09 |
Novartis Ag |
Organic Compound
|
JP4890762B2
(ja)
|
2002-09-25 |
2012-03-07 |
メモリー・ファーマシューティカルズ・コーポレイション |
インダゾール、ベンゾチアゾール、及びベンゾイソチアゾール、並びにそれらの調製及び使用
|
EP1562959A2
(en)
*
|
2002-11-01 |
2005-08-17 |
Pharmacia & Upjohn Company LLC |
Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
|
JP4750421B2
(ja)
*
|
2002-12-06 |
2011-08-17 |
ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト |
α7受容体結合コリン作動性アゴニストを用いる炎症の阻害
|
US7238715B2
(en)
*
|
2002-12-06 |
2007-07-03 |
The Feinstein Institute For Medical Research |
Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
|
JP2006521345A
(ja)
*
|
2003-03-28 |
2006-09-21 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
ニコチン性アセチルコリン受容体の正のアロステリック調節剤
|
GB0310867D0
(en)
|
2003-05-12 |
2003-06-18 |
Novartis Ag |
Organic compounds
|
DE10334724A1
(de)
*
|
2003-07-30 |
2005-02-24 |
Bayer Healthcare Ag |
N-Biarylamide
|
DK1678172T3
(da)
|
2003-10-15 |
2010-04-06 |
Targacept Inc |
Azabicykliske forbindelser til lindring af smerte og behandling af sygdomme i centralnervesystemet
|
US20050137217A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
Spirocyclic quinuclidinic ether derivatives
|
DE602004010299T2
(de)
|
2003-12-22 |
2008-09-18 |
Memory Pharmaceuticals Corp. |
Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
|
AU2005227324A1
(en)
|
2004-03-25 |
2005-10-06 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
DE602005024677D1
(de)
|
2004-04-22 |
2010-12-23 |
Memory Pharm Corp |
Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
|
WO2005111038A2
(en)
|
2004-05-07 |
2005-11-24 |
Memory Pharmaceuticals Corporation |
1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
|
PE20060437A1
(es)
|
2004-06-18 |
2006-06-08 |
Novartis Ag |
COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
GB0424564D0
(en)
*
|
2004-11-05 |
2004-12-08 |
Novartis Ag |
Organic compounds
|
CN101124224A
(zh)
|
2004-12-22 |
2008-02-13 |
记忆药物公司 |
烟碱性α-7受体配体及其制备和用途
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
WO2006073484A2
(en)
|
2004-12-27 |
2006-07-13 |
North Shore-Long Island Jewish Research Institute |
Treating inflammatory disorders by electrical vagus nerve stimulation
|
JP2009506037A
(ja)
|
2005-08-22 |
2009-02-12 |
ターガセプト,インコーポレイテッド |
ヘテロアリール置換ジアザトリシクロアルカン、その調製方法およびその使用方法
|
US8106066B2
(en)
|
2005-09-23 |
2012-01-31 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
|
GB0521508D0
(en)
|
2005-10-21 |
2005-11-30 |
Novartis Ag |
Organic compounds
|
US8316104B2
(en)
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
GB0525673D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
GB0525672D0
(en)
|
2005-12-16 |
2006-01-25 |
Novartis Ag |
Organic compounds
|
TWI405763B
(zh)
*
|
2006-11-02 |
2013-08-21 |
Targacept Inc |
菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
|
CL2008000119A1
(es)
|
2007-01-16 |
2008-05-16 |
Wyeth Corp |
Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
|
EP2119716A4
(en)
*
|
2007-02-09 |
2011-06-01 |
Astellas Pharma Inc |
AZA BRIDGE CYCLE COMPOUND
|
WO2009013535A1
(en)
*
|
2007-07-23 |
2009-01-29 |
Astrazeneca Ab |
2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
WO2009029614A1
(en)
|
2007-08-27 |
2009-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
CN101883771A
(zh)
|
2007-10-01 |
2010-11-10 |
科门蒂斯公司 |
作为α7-烟碱乙酰胆碱受体配体用于治疗阿尔茨海默氏病的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
|
EP2254598B1
(en)
|
2008-02-13 |
2013-07-10 |
Targacept, Inc. |
Combination of alpha 7 nicotinic agonists and antipsychotics
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
WO2009146030A1
(en)
|
2008-03-31 |
2009-12-03 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of t-cell activity
|
EA201001889A1
(ru)
|
2008-06-20 |
2011-08-30 |
Астразенека Аб |
Производные дибензотиазепина и их применение
|
CN102215909B
(zh)
|
2008-11-18 |
2014-09-10 |
赛博恩特医疗器械公司 |
优化用于消炎刺激的电极放置的装置和方法
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
WO2010087762A1
(en)
*
|
2009-01-28 |
2010-08-05 |
Astrazeneca Ab |
2-aza-bicyclo[2.2.1]heptane compounds and uses thereof
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
EP2440284B1
(en)
|
2009-06-09 |
2018-09-12 |
Setpoint Medical Corporation |
Nerve cuff with pocket for leadless stimulator
|
FR2948368B1
(fr)
*
|
2009-07-21 |
2011-07-22 |
Servier Lab |
Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US11051744B2
(en)
|
2009-11-17 |
2021-07-06 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
CN102821814B
(zh)
|
2009-12-23 |
2015-07-15 |
赛博恩特医疗器械公司 |
用于治疗慢性炎症的神经刺激设备和系统
|
RS56812B1
(sr)
|
2010-05-17 |
2018-04-30 |
Forum Pharmaceuticals Inc |
Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-hloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidrohlorid monohidrata
|
US10449177B2
(en)
|
2010-08-19 |
2019-10-22 |
Buck Institute For Research On Aging |
Methods of treating mild cognitive impairment (MCI) and related disorders
|
WO2012154865A2
(en)
|
2011-05-09 |
2012-11-15 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
GB201111704D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Novel compounds
|
GB201111705D0
(en)
|
2011-07-07 |
2011-08-24 |
Takeda Pharmaceutical |
Compounds and their use
|
JO3115B1
(ar)
|
2011-08-22 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مركبات بيريدازينون واستخدامها كمثبطات daao
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
WO2013169646A1
(en)
|
2012-05-08 |
2013-11-14 |
Envivo Pharmaceuticals, Inc. |
Methods of maintaining, treating or improving cognitive function
|
GB201209587D0
(en)
|
2012-05-30 |
2012-07-11 |
Takeda Pharmaceutical |
Therapeutic compounds
|
JOP20130273B1
(ar)
*
|
2012-09-11 |
2021-08-17 |
Genzyme Corp |
مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
|
JP6478923B2
(ja)
|
2013-02-07 |
2019-03-06 |
ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited |
ムスカリンm4受容体アゴニストとしてのピペリジン−1−イル及びアゼピン−1−イルカルボキシレート
|
HUE064200T2
(hu)
*
|
2013-03-15 |
2024-02-28 |
Genzyme Corp |
Eljárás glukozilceramid szintáz inhibitorok elõállítására
|
AU2014282977B2
(en)
|
2013-06-21 |
2018-06-14 |
Takeda Pharmaceutical Company Limited |
1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
|
GB201314286D0
(en)
|
2013-08-08 |
2013-09-25 |
Takeda Pharmaceutical |
Therapeutic Compounds
|
GB201318222D0
(en)
|
2013-10-15 |
2013-11-27 |
Takeda Pharmaceutical |
Novel compounds
|
GB201320905D0
(en)
|
2013-11-27 |
2014-01-08 |
Takeda Pharmaceutical |
Therapeutic compounds
|
TW201613864A
(en)
|
2014-02-20 |
2016-04-16 |
Takeda Pharmaceutical |
Novel compounds
|
JP2017524736A
(ja)
|
2014-07-11 |
2017-08-31 |
アルファーマゲン,エルエルシー |
アルファ7−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
US11406833B2
(en)
|
2015-02-03 |
2022-08-09 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
WO2017127758A1
(en)
|
2016-01-20 |
2017-07-27 |
Setpoint Medical Corporation |
Implantable microstimulators and inductive charging systems
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
EP3405107B1
(en)
|
2016-01-20 |
2023-04-12 |
Setpoint Medical Corporation |
Control of vagal stimulation
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
GB201616839D0
(en)
|
2016-10-04 |
2016-11-16 |
Takeda Pharmaceutical Company Limited |
Therapeutic compounds
|
GB201619514D0
(en)
|
2016-11-18 |
2017-01-04 |
Takeda Pharmaceuticals Co |
Novel compounds
|
DE102017210141A1
(de)
|
2017-06-16 |
2018-12-20 |
Henkel Ag & Co. Kgaa |
Portion zur Bereitstellung tensidhaltiger Flotten
|
US11173307B2
(en)
|
2017-08-14 |
2021-11-16 |
Setpoint Medical Corporation |
Vagus nerve stimulation pre-screening test
|
US11660443B2
(en)
|
2018-04-20 |
2023-05-30 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
US20230002380A1
(en)
*
|
2019-11-15 |
2023-01-05 |
Yuhan Corporation |
Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
|
CA3154313A1
(en)
*
|
2019-11-15 |
2021-05-20 |
Dong-Hoon Kim |
Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
|
JP2021138648A
(ja)
|
2020-03-04 |
2021-09-16 |
武田薬品工業株式会社 |
経口固形製剤
|
WO2021236977A1
(en)
|
2020-05-21 |
2021-11-25 |
The Feinstein Institutes For Medical Research |
Systems and methods for vagus nerve stimulation
|
US11857512B2
(en)
|
2020-07-24 |
2024-01-02 |
Genzyme Corporation |
Pharmaceutical compositions comprising venglustat
|
KR20220153511A
(ko)
*
|
2021-05-11 |
2022-11-18 |
주식회사유한양행 |
글루코실세라마이드 합성효소에 대한 저해 활성을 갖는 신규의 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
|
WO2024090917A1
(en)
*
|
2022-10-24 |
2024-05-02 |
Yuhan Corporation |
Novel salt of dimethyl-2,3-dihydro-1h-indene derivative and processes for preparing the same
|
WO2024090919A1
(en)
*
|
2022-10-24 |
2024-05-02 |
Yuhan Corporation |
Improved processes for preparing dimethyl-2,3-dihydro-1h-indene derivatives
|